Back

The SGLT-2 inhibitor empagliflozin improves myocardial strain,ejection fraction, reduces pro-inflammatory cytokines and H-FABP/troponin in models of anthracyline-induced cardiotoxicity

11 December 2024 (00:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: Imaging in cardio-oncology Myocardial Disease EACVI Premium Access EuroEcho-Imaging 2024 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Association of echocardiographic radiomics-based features with cardiotoxicity effect in breast cancer patients from the CARDIOCARE project
Assistant Professor L. Lakkas (Ioannina, GR)
Abstract Slides
Presentation thumbnail
Natural shear wave elastography reveals hidden cardiac dysfunction in adult survivors of childhood cancer during cardiopulmonary stress testing
Doctor A. Youssef (Leuven, BE)
Abstract Slides
Presentation thumbnail
Oxidative stress biomarkers and myocardial dysfunction in a doxorubicin- and trastuzumab-induced rat model of cardiomyopathy
Associate Professor D. Cho (Seoul, KR)
Abstract Slides
Presentation thumbnail
Right ventricular strain as a predictor of trastuzumab-induced chemotherapy-related cardiac dysfunction: a meta-analysis
Doctor I. Scott (Newcastle Upon Tyne, GB)
Abstract Slides

Access the full session

Session thumbnail
Imaging in cardio-oncology

The Event

Event poster

EuroEcho-Imaging 2024

11 December - 13 December 2024
You may be interested in
thumbnail
Congress Presentation
Echocardiography as first-line technique in suspected cardiac amyloidosis
thumbnail
Congress Presentation
Dilated cardiomyopathy
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources